Skip to main content
MEDIPOSTCO.,LTD. logo

MEDIPOSTCO.,LTD. — Investor Relations & Filings

Ticker · 078160 ISIN · KR7078160009 KO Manufacturing
Open in API
Filings indexed 366 across all filing types
Latest filing 2023-10-13 Major Shareholding Noti…
Country KR South Korea
Listing KO 078160

About MEDIPOSTCO.,LTD.

https://en.medi-post.co.kr/

MEDIPOST is a biotechnology company specializing in the research, development, and commercialization of stem cell therapeutics and regenerative medicine. The company focuses on addressing unmet medical needs for incurable diseases through its proprietary stem cell platform technology. Its core operations include a cord blood banking service and the development of allogeneic stem cell therapies. Key commercialized products include CARTISTEM®, a treatment for knee cartilage defects and osteoarthritis, and PNEUMOSTEM®, a preventive therapy for bronchopulmonary dysplasia in premature infants. The company's clinical pipeline features next-generation injectable treatments for conditions such as osteoarthritis and diabetic nephropathy.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a major shareholder or executive changes their stake in a company. This specific document details a change in shareholding (specifically the acquisition of new share warrants) by 'SkyMedi Limited' in 'Medipost Co., Ltd.'. This falls under the category of Major Shareholding Notification (MRQ) as it reports a change in significant share ownership levels.
2023-10-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service and the Korea Exchange. This type of filing is specifically used to disclose changes in shareholdings by major shareholders (in this case, SkyMedi Limited, a 10% or greater shareholder of Medipost Co., Ltd.). This falls under the category of Major Shareholding Notification (MRQ) as it tracks significant ownership changes and threshold reporting.
2023-10-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (DART). This type of filing is a mandatory disclosure for major shareholders (insiders) to report changes in their shareholdings, which falls under the category of Major Shareholding Notification (MRQ).
2023-10-05 Korean
기타경영사항(자율공시)(국책과제 선정(글로벌 경쟁력 확보 가능한 동물유래성분대체 배양배지 기반 고도화된 줄기세포치료제 임상시료 제조기술 개발))
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure ('자율공시') from MediPost regarding the selection of a government-funded research project. It details the project scope, duration, funding amounts, and objectives related to stem cell therapy manufacturing technology. Since this is a specific corporate announcement regarding business operations and R&D activities that does not fit into financial reporting, dividend, or governance categories, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2023-09-27 Korean
기타경영사항(자율공시)(전환우선주 전환가액 조정)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Medipost regarding the adjustment of the conversion price for convertible preferred shares. This type of disclosure, which involves changes to the capital structure and conversion terms of financial instruments, falls under 'Capital/Financing Update' (CAP) as it directly relates to the company's financing activities and capital structure adjustments.
2023-09-26 Korean
유상증자1차발행가액결정
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Medi-Post regarding the determination of the first issue price for a paid-in capital increase (rights offering). It details the calculation methodology, the specific price per share, and the timeline for the final price determination. This falls under the category of capital and financing updates, specifically related to share issuance and capital structure changes.
2023-09-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.